Moderna Says Second Covid-19 Vaccine Generates Strong Immune Response

Dow Jones

Sep 23

By Nicholas G. Miller

Moderna said its updated mNexspike Covid-19 vaccine demonstrated a strong immune response against the dominant LP.8.1 variant, after previously saying its other Covid-19 vaccine, Spikevax, also demonstrated a strong immune response.

Data from an ongoing Phase 4 trial showed mNexspike produced a 16-fold increase in antibodies neutralizing LP.8.1. It said earlier this month that Spikevax generated an eight-fold increase in antibodies.

The 2025-2026 formula of mNexspike is approved for individuals 12 through 64 years of age with at least one underlying condition putting them at a high risk for severe outcomes from Covid-19 and all adults 65 years of age and older.

Write to Nicholas G. Miller at nicholas.miller@wsj.com.

(END) Dow Jones Newswires

September 23, 2025 07:27 ET (11:27 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2569926287"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2569926287\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2569926287?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-23 19:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2569926287","market":"other","top_or_hot":-1,"title":"Moderna Says Second Covid-19 Vaccine Generates Strong Immune Response","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Nicholas G. Miller \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/MRNA\">Moderna</a> said its updated mNexspike Covid-19 vaccine demonstrated a strong immune response against the dominant LP.8.1 variant, after previously saying its other Covid-19 vaccine, Spikevax, also demonstrated a strong immune response. \n</p>\n<p>\n  Data from an ongoing Phase 4 trial showed mNexspike produced a 16-fold increase in antibodies neutralizing LP.8.1. It said earlier this month that Spikevax generated an eight-fold increase in antibodies. \n</p>\n<p>\n  The 2025-2026 formula of mNexspike is approved for individuals 12 through 64 years of age with at least one underlying condition putting them at a high risk for severe outcomes from Covid-19 and all adults 65 years of age and older. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Nicholas G. Miller at nicholas.miller@wsj.com. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  September 23, 2025 07:27 ET (11:27 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Says Second Covid-19 Vaccine Generates Strong Immune Response</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Says Second Covid-19 Vaccine Generates Strong Immune Response\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-09-23 19:27</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Nicholas G. Miller \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/MRNA\">Moderna</a> said its updated mNexspike Covid-19 vaccine demonstrated a strong immune response against the dominant LP.8.1 variant, after previously saying its other Covid-19 vaccine, Spikevax, also demonstrated a strong immune response. \n</p>\n<p>\n  Data from an ongoing Phase 4 trial showed mNexspike produced a 16-fold increase in antibodies neutralizing LP.8.1. It said earlier this month that Spikevax generated an eight-fold increase in antibodies. \n</p>\n<p>\n  The 2025-2026 formula of mNexspike is approved for individuals 12 through 64 years of age with at least one underlying condition putting them at a high risk for severe outcomes from Covid-19 and all adults 65 years of age and older. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Nicholas G. Miller at nicholas.miller@wsj.com. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  September 23, 2025 07:27 ET (11:27 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BNTX","symbol_name":"BioNTech SE","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2569926287","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2569926287","pubTimestamp":1758626820,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Moderna said its updated mNexspike Covid-19 vaccine demonstrated a strong immune response against the dominant LP.8.1 variant, after previously saying its other Covid-19 vaccine, Spikevax, also demonstrated a strong immune response.Data from an ongoing Phase 4 trial showed mNexspike produced a 16-fold increase in antibodies neutralizing LP.8.1. It said earlier this month that Spikevax generated an eight-fold increase in antibodies.The 2025-2026 formula of mNexspike is approved for individuals 12 through 64 years of age with at least one underlying condition putting them at a high risk for severe outcomes from Covid-19 and all adults 65 years of age and older.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BNTX":"BioNTech SE","BK4551":"寇图资本持仓","BK4568":"美国抗疫概念","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK4534":"瑞士信贷持仓","MRNA":"Moderna, Inc.","BK4548":"巴美列捷福持仓","BK4535":"淡马锡持仓","BK4532":"文艺复兴科技持仓","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4501":"段永平概念"},"translate_title":"Moderna称第二种Covid-19疫苗可产生强烈免疫反应","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BNTX":1.5,"MRNA":0.9},"content_text":"By Nicholas G. Miller \n\n\n \n\n\nModerna said its updated mNexspike Covid-19 vaccine demonstrated a strong immune response against the dominant LP.8.1 variant, after previously saying its other Covid-19 vaccine, Spikevax, also demonstrated a strong immune response. \n\n\n  Data from an ongoing Phase 4 trial showed mNexspike produced a 16-fold increase in antibodies neutralizing LP.8.1. It said earlier this month that Spikevax generated an eight-fold increase in antibodies. \n\n\n  The 2025-2026 formula of mNexspike is approved for individuals 12 through 64 years of age with at least one underlying condition putting them at a high risk for severe outcomes from Covid-19 and all adults 65 years of age and older. \n\n\n \n\n\n  Write to Nicholas G. Miller at nicholas.miller@wsj.com. \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  September 23, 2025 07:27 ET (11:27 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}